The first International Center of Excellence from Australia is acknowledged for their staff’s assurance to improving the quality of life of patients with foot and ankle disorders by using state-of-the-
A significant number of children and adults suffer lack of mobility and pain from excessive hindfoot motion, also known as congenital/acquired talotarsal joint dislocation and hyperpronation, a surgically correctable condition that results in the misalignment of the foot and other major structures of the body. The minimally invasive HyProCure® EOTTS procedure provides many patients with immediate and permanent correction for congenital/acquired talotarsal joint dislocation. Left untreated, congenital/acquired talotarsal joint dislocation can lead to serious, long-term foot, knee, hip, and back related issues that often require much more aggressive forms of surgery.
GraMedica® is the Macomb, Michigan developer and manufacturer of HyProCure®, a surgical stent that has been used in over 27,000 procedures worldwide to treat congenital/acquired talotarsal joint dislocation. HyProCure® International Center of Excellence is a program to reach out to a large patient population, designed to increase the awareness and medical services provided by experts in foot and ankle care.
Future announcements are expected regarding GraMedica’s HyProCure® International Centers of Excellence located in other parts of the world.
For more information Email: international@